Abstract Number: 1349 • ACR Convergence 2023
Paternal Effects of Anti-TNFs in Inflammatory Arthritis
Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…Abstract Number: 2278 • ACR Convergence 2023
Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry
Background/Purpose: Pregnancy in patients with connective tissue diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aim toevaluate…Abstract Number: 0474 • ACR Convergence 2023
Acute Cardiovascular Events During Pregnancy and Delivery in Patients with Autoimmune Rheumatic Diseases (ARDs): An Analysis of National Inpatient Sample
Background/Purpose: Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) & vasculitis are autoimmune rheumatic diseases (ARDs) with systemic involvement. Management of women with ARDs during pregnancy…Abstract Number: 1350 • ACR Convergence 2023
Identification of ACR Guidelines for SLE Pregnancy Care in the Electronic Health Record
Background/Purpose: SLE is an autoimmune disease with an increased risk for poor outcomes in pregnancy. In 2020, ACR specified several recommendations to assist clinicians in…Abstract Number: 2292 • ACR Convergence 2023
Is Machine Learning Useful to Predict Flare During Pregnancy in Systemic Lupus Erythematosus?
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients are at risk of disease flare during pregnancy; risk stratification is crucial for personalized treatment and monitoring. Our hypothesis…Abstract Number: 0475 • ACR Convergence 2023
Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States
Background/Purpose: Endometriosis (ENDO) and Polycystic Ovarian Syndrome (PCOS) are underdiagnosed, often debilitating conditions with unknown etiologies that, like rheumatic diseases, affect reproductive-aged women. Recent studies…Abstract Number: 1352 • ACR Convergence 2023
Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study
Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis which affects women of reproductive age. There is limited information about the effect of TA on…Abstract Number: 2305 • ACR Convergence 2023
Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age. Pregnant women with SLE have higher rates of…Abstract Number: 0476 • ACR Convergence 2023
Factors Associated with the Need for Assisted Reproductive Therapies in a Spanish Cohort of Patients with Rheumatic Diseases
Background/Purpose: Patients with rheumatic diseases (RMD) have a lower pregnancy rate, with infertility being one of the main causes. The rate of assisted reproductive therapies…Abstract Number: 1354 • ACR Convergence 2023
The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus
Background/Purpose: Mental health conditions are the leading cause of maternal mortality across most of the United States. Among individuals with SLE, pregnancy intention has been…Abstract Number: 2425 • ACR Convergence 2023
Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data
Background/Purpose: Systemic vasculitides are rare, heterogeneous, inflammatory disorders associated with high morbidity and mortality. Recent management and therapeutic advances have improved life expectancy and reproductive…Abstract Number: 0477 • ACR Convergence 2023
Continuing TNFi After Pregnancy Diagnosis in Women with Chronic Rheumatic Inflammatory Diseases Is Not Associated with Worse Obstetrical or Infant Outcomes and Seems to Reduce Risk of Maternal Severe Infection: The Results of the Emulated Target Trial BioGRIC
Background/Purpose: Many women with chronic rheumatic inflammatory diseases (CRID) stop tumor necrosis factor inhibitors (TNFi) treatment once pregnancy is confirmed to avoid potential adverse fetal…Abstract Number: 1355 • ACR Convergence 2023
Delivering Care for Pregnant Women with Rheumatic and Musculoskeletal Diseases in Ireland: Current Challenges and Practices
Background/Purpose: Rheumatic disease frequently affects women of childbearing age. Women with pre-existing rheumatic disease who are planning a pregnancy or develop these conditions during pregnancy…Abstract Number: 2481 • ACR Convergence 2023
Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy
Background/Purpose: Rheumatoid arthritis (RA) can improve naturally during pregnancy in a substantial proportion of women (50-75%), while it may worsen or remain unchanged in others.…Abstract Number: 0103 • ACR Convergence 2023
Criteria and Non-criteria Antiphospholipid Autoantibodies Screening in Women with Unexplained Fetal Death, Pre-eclampsia And/or Fetal Growth Restriction: A Cross-sectional Study
Background/Purpose: Antiphospholipid syndrome (APS) is a cause of pregnancy morbidity. Late pregnancy morbidity occurs in up to 25% of pregnant women with APS and may…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 22
- Next Page »